Haemate (Human Coagulation Factor Viii, Human Von Willebrand Factor)

Haemate is indicated for the management of bleeding disorders that involve deficiencies of factor VIII and von Willebrand factor.

• Routine prophylaxis to prevent spontaneous bleeding episodes in patients with severe hemophilia A.
• On‑demand treatment of acute bleeding episodes in hemophilia A.
• Management of bleeding episodes associated with von Willebrand disease types 1, 2, and 3.
• Perioperative coverage to maintain hemostasis during surgical or dental procedures in affected individuals.
• Adjunct therapy in patients undergoing invasive diagnostics where adequate clotting support is required.

Adverse reactions reported with Haemate reflect the typical safety profile of plasma‑derived clotting factor concentrates.

Common

• Mild infusion‑site reactions such as erythema, warmth, or transient pain.
• Headache or fatigue occurring shortly after administration.
• Low‑grade fever or chills without evidence of infection.
• Transient nausea or vomiting during or after infusion.

Serious

• Allergic or anaphylactic reactions, including urticaria, bronchospasm, or hypotension.
• Development of inhibitors (neutralizing antibodies) against factor VIII, reducing therapeutic efficacy.
• Transmission of infectious agents, although rare, remains a theoretical risk with plasma‑derived products.
• Thrombotic events such as deep‑vein thrombosis in patients with pre‑existing risk factors.

When prescribing Haemate, clinicians should consider several precautionary measures to ensure safe and effective use.

• Assess patient history for previous allergic reactions to plasma‑derived products.
• Screen for existing inhibitors to factor VIII before initiating therapy.
• Monitor for signs of infection or febrile reactions during and after infusion.
• Use caution in patients with cardiovascular disease or a history of thrombosis.
• Adjust dosing in individuals with renal or hepatic impairment as clinically indicated.
• Educate patients on proper storage, handling, and disposal of the injectable solution.

Haemate may interact with other medications or biologics that affect hemostasis or immune response.

Avoid

• Concurrent use of other factor concentrates or bypassing agents without specialist guidance.
• Administration with investigational gene‑therapy products targeting factor VIII.

Use with caution

• Antifibrinolytic agents (e.g., tranexamic acid) may increase clot stability; monitor for excessive thrombosis.
• Immunosuppressive drugs can alter inhibitor development risk; coordinate care with hematology.
• Vaccines, especially live attenuated, should be timed appropriately around infusion to avoid immune interference.